Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506900PMC
http://dx.doi.org/10.1164/rccm.202404-0796RLDOI Listing

Publication Analysis

Top Keywords

inhaled corticosteroids
4
corticosteroids attenuate
4
attenuate association
4
association fine
4
fine particulate
4
particulate matter
4
matter acute
4
acute asthma
4
asthma events
4
inhaled
1

Similar Publications

Treatment patterns for chronic obstructive pulmonary disease under the tiered medical system.

Sci Rep

January 2025

Department of Respiratory and Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.

China has implemented the "tiered medical services" policy since 2015, while there is a paucity of data evaluating the the current status of chronic obstructive pulmonary disease (COPD) management under the system. Characteristics and treatments from 11,905 COPD patients in 88 hospitals across different tiers in China were included and analyzed. We assessed the statistical significance of differences by one way analysis of variance (ANOVA) for continuous variables and with the chi-squared test for categorical variables.

View Article and Find Full Text PDF

The cardiovascular effects of long-acting bronchodilators inhalers and inhaled corticosteroids purchases among asthma and COPD patients.

Heart Lung

January 2025

Adelson School of Medicine, Ariel University, 3 Kiryat Hamada St., Ariel, Israel; Pulmonary Clinic, Dan- Petah-Tiqwa District, Clalit Health Services Community Division, 25 Hamytar St., Ramat-Gan, Israel. Electronic address:

Background: Confounding reports of cardiovascular disease (CVD) with the use of Inhaled corticosteroids (ICS), long-acting beta-agonists, and muscarinic antagonists (LABA and LAMA) have been reported.

Objective: To explore the relationship between the purchase of ICS, LABA and LAMA inhalers and the incidence of CVDs.

Methods: This retrospective study included patients with COPD and/or asthma, aged ≥ 18 years, who purchased LABA, LAMA, and ICS inhalers alone or in combination between 2017 and 2019.

View Article and Find Full Text PDF

Background: Studies suggest that asthma and hypertension may be comorbid conditions. Most of these studies are epidemiological research. However, data on the relationship between asthma and hypertension in childhood are limited.

View Article and Find Full Text PDF

The first combination inhaled corticosteroid and short-acting beta₂ agonist (ICS-SABA) was approved by the Food and Drug Administration (FDA) in 2023 for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in patients 18 years of age and older. The recently approved product contains an ICS-albuterol combination. The 2024 Global Initiative for Asthma (GINA) guidelines recommend as-needed ICS-formoterol as the preferred asthma reliever therapy; however, a GINA alternative recommendation is the use of ICS whenever an as-needed (SABA) is used.

View Article and Find Full Text PDF

The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!